Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated May 18, 2026 (5 months ago)

Lidocaine HCl Injection (Lidocaine, Kenalog, Povidone Iodine)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520. NDC: 55150-164-02

Affected NDC 55150-0164-02

Compare with the code on your package — it is the most precise check available.

Drug: Lidocaine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Lidocaine Hydrochloride
NDC 55150-0164
20 mg/mL Injection, Solution
Epidural|infiltration|intracaudal|perineural
Eugia US LLC Rx
Recalling firm
Eugia US LLC
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0552-2026 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Lidocaine recalls

See all
Class II · Moderate risk

Lidocaine Ointment USP

Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

Ongoing Wrong potency / content Sun Pharma /Taro D-0848-2026
Class III · Low risk

Lidolog Kit

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Asclemed USA Inc. D-0713-2026

Other recalls by Eugia US LLC

All 2026 recalls
Class II · Moderate risk

Gentamicin Injection

Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Ongoing Stability / shelf life Eugia US LLC NDC 55150-401-01 D-0472-2025
Class II · Moderate risk

Testosterone Cypionate Injection

cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.

Ongoing cGMP deviation Eugia US LLC NDC 55150-277-01 D-0363-2025